desipramine has been researched along with Hypertension in 33 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cardiovascular effects of desipramine were assessed in 74 young women with bulimia nervosa participating in a 6-week double-blind, placebo-controlled study." | 9.07 | Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa. ( Hadigan, CM; Walsh, BT; Wong, LM, 1992) |
| "We infused tracer-labeled l-[3H]-norepinephrine, d-[14C]norepinephrine, and d,l-[3H]-isoproterenol simultaneously into patients with essential hypertension and into normotensive control subjects, in order to determine whether abnormalities in the disappearance kinetics of these substances characterized the hypertensive patients." | 7.66 | Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension. ( Goldstein, DS; Horwitz, D; Keiser, HR; Kopin, IJ; Polinsky, RJ, 1983) |
| "The cardiovascular effects of desipramine were assessed in 74 young women with bulimia nervosa participating in a 6-week double-blind, placebo-controlled study." | 5.07 | Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa. ( Hadigan, CM; Walsh, BT; Wong, LM, 1992) |
| "We infused tracer-labeled l-[3H]-norepinephrine, d-[14C]norepinephrine, and d,l-[3H]-isoproterenol simultaneously into patients with essential hypertension and into normotensive control subjects, in order to determine whether abnormalities in the disappearance kinetics of these substances characterized the hypertensive patients." | 3.66 | Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension. ( Goldstein, DS; Horwitz, D; Keiser, HR; Kopin, IJ; Polinsky, RJ, 1983) |
| "Hypertension is associated with enhanced cardiac sympathetic transmission, although the exact mechanisms underlying this are still unknown." | 1.39 | Ganglion-specific impairment of the norepinephrine transporter in the hypertensive rat. ( Mane, S; Paterson, DJ; Ryan, R; Shanks, J, 2013) |
| " However, it is also known to accumulate in various tissues up to several times higher after standard oral dosing and we now have evidence from both in vivo and in vitro experiments with spontaneously hypertensive rats (SHR) that millimolar levels stimulate release of norepinephrine (NE) from vascular sympathetic nerve endings (SNEs)." | 1.31 | A possible indirect sympathomimetic action of metformin in the arterial vessel wall of spontanously hypertensive rats. ( Lee, JM; Peuler, JD, 2001) |
| " Full dose-response curves to noradrenaline, vasopressin and potassium chloride were established." | 1.28 | Increased sensitivity to noradrenaline in glucocorticoid-treated rats: the effects of indomethacin and desipramine. ( Fraser, R; Kenyon, CJ; Russo, D, 1990) |
| "Pretreatment with desipramine decreased significantly the removal of NE to virtually exactly that of ISO." | 1.27 | Measurement of regional neuronal removal of norepinephrine in man. ( Folio, J; Goldstein, DS; Keiser, HR; Kopin, IJ; Levinson, PD; Stull, R; Zimlichman, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (72.73) | 18.7374 |
| 1990's | 4 (12.12) | 18.2507 |
| 2000's | 4 (12.12) | 29.6817 |
| 2010's | 1 (3.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shanks, J | 1 |
| Mane, S | 1 |
| Ryan, R | 1 |
| Paterson, DJ | 1 |
| Schlaich, MP | 1 |
| Lambert, E | 1 |
| Kaye, DM | 1 |
| Krozowski, Z | 1 |
| Campbell, DJ | 1 |
| Lambert, G | 1 |
| Hastings, J | 1 |
| Aggarwal, A | 1 |
| Esler, MD | 1 |
| Wilens, TE | 1 |
| Hammerness, PG | 1 |
| Biederman, J | 1 |
| Kwon, A | 1 |
| Spencer, TJ | 1 |
| Clark, S | 1 |
| Scott, M | 1 |
| Podolski, A | 1 |
| Ditterline, JW | 1 |
| Morris, MC | 1 |
| Moore, H | 1 |
| Schmitt, H | 4 |
| Goldstein, DS | 3 |
| Horwitz, D | 1 |
| Keiser, HR | 3 |
| Polinsky, RJ | 1 |
| Kopin, IJ | 3 |
| Esler, M | 1 |
| Jackman, G | 1 |
| Leonard, P | 1 |
| Bobik, A | 1 |
| Skews, H | 1 |
| Jennings, G | 1 |
| Kelleher, D | 1 |
| Korner, P | 1 |
| Cabassi, A | 1 |
| Vinci, S | 1 |
| Quartieri, F | 1 |
| Moschini, L | 1 |
| Borghetti, A | 1 |
| Lee, JM | 1 |
| Peuler, JD | 1 |
| Scriabine, A | 2 |
| Clineschmidt, BV | 1 |
| Sweet, CS | 2 |
| Ludden, CT | 1 |
| Stavorski, JM | 1 |
| Wenger, HC | 1 |
| Bohidar, NR | 1 |
| Petersen, EN | 1 |
| Ogawa, M | 1 |
| Bevan, JA | 1 |
| Bevan, RD | 1 |
| Chang, PC | 1 |
| Pegram, BL | 1 |
| Purdy, RE | 1 |
| Su, C | 1 |
| Burgess, CD | 1 |
| Turner, P | 2 |
| Wadsworth, J | 1 |
| Finch, L | 1 |
| Hersom, A | 1 |
| Hicks, P | 1 |
| Walsh, BT | 1 |
| Hadigan, CM | 1 |
| Wong, LM | 1 |
| Ludwig, J | 2 |
| Halbrügge, T | 2 |
| Graefe, KH | 2 |
| Gerlich, M | 1 |
| Russo, D | 1 |
| Fraser, R | 1 |
| Kenyon, CJ | 1 |
| van den Buuse, M | 1 |
| de Jong, W | 1 |
| Dawson, R | 1 |
| Nagahama, S | 1 |
| Oparil, S | 1 |
| Zimlichman, R | 2 |
| Stull, R | 2 |
| Folio, J | 1 |
| Levinson, PD | 1 |
| Guilleminault, C | 1 |
| Carskadon, M | 1 |
| Dement, WC | 1 |
| de White, C | 1 |
| Royds, RB | 1 |
| Briant, RH | 1 |
| Reid, JL | 1 |
| Dollery, CT | 1 |
| Oates, JA | 3 |
| Mitchell, JR | 3 |
| Feagin, OT | 1 |
| Kaufmann, JS | 1 |
| Shand, DG | 1 |
| Cavanaugh, JH | 1 |
| Arias, L | 2 |
| Jacquot, C | 1 |
| Bralet, J | 1 |
| Cohen, Y | 1 |
| Valette, G | 1 |
| Schuckit, M | 1 |
| Robins, E | 1 |
| Feighner, J | 1 |
| Bonaccorsi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Renal SympAthetic DenerVation on Chronic HypErtension[NCT01628198] | 38 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to recommendation by the study's DSMB due to insufficient data to determine efficacy.) | |||
| Renal Sympathetic Denervation for the Management of Chronic Hypertension[NCT01628172] | 96 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| Plasma Catecholamine Kinetics[NCT00001329] | 50 participants | Observational | 1992-09-30 | Completed | |||
| Safety and Efficacy of Intravenous Norepinephrine for Orthostatic Hypotension[NCT01285908] | Phase 1/Phase 2 | 6 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in diastolic blood pressure as measured by 24 hour ambulatory monitoring at 6 months as compared to from baseline. (NCT01628198)
Timeframe: baseline and 6 months
| Intervention | mmHg mean change (Mean) |
|---|---|
| Renal Denervation Group | -5.5 |
The change in systolic blood pressure as measured by 24 hour ambulatory monitoring at 6 months as compared to from baseline. (NCT01628198)
Timeframe: baseline and 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Renal Denervation Group | -10.2 |
The total number of anti-hypertensive medications at baseline, 6 months, and 12 months (NCT01628198)
Timeframe: Baseline, 6 months, 12 months
| Intervention | medications (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 5.37 | 4.79 | 4.64 |
A blood urea nitrogen (BUN) test measures the amount of nitrogen in blood that comes from the waste product urea. Urea is made when protein is broken down in the body. Urea is made in the liver and passed out in the urine. (NCT01628198)
Timeframe: baseline, 6 months, 12 months
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 20.82 | 22.15 | 23.11 |
Creatinine measures the level of the waste product in the body. The amount of creatinine in the blood depends partly on the amount of muscle tissue you have. Men generally have higher creatinine levels than women.Normal levels of creatinine in the blood are approximately 0.6 to 1.2 milligrams (mg) per deciliter (dL) in adult males and 0.5 to 1.1 milligrams per deciliter in adult females. High levels of creatinine indicates kidney impairment. (NCT01628198)
Timeframe: baseline, 6 months, 12 months
| Intervention | mg/dl (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 1.6 | 1.68 | 2.03 |
Different time points office diastolic blood pressure measurements (NCT01628198)
Timeframe: baseline, 6 month, 12 months
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 87.06 | 86.93 | 87.75 |
Different time points office systolic blood pressure measurements (NCT01628198)
Timeframe: baseline, 6 month, 12 months
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Renal Denervation Group | 156.86 | 151.19 | 158.45 |
Renal artery blood flow as measured by Renal Aortic Ratio (RAR) = Peak systolic Velocity renal artery / Peak Systolic Velocity Aorta. A >60% stenosis is reported when there is a >3.5:1 Renal to Aortic Ratio. (NCT01628198)
Timeframe: Baseline and 12 months
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Baseline Right RAR | Baseline Left RAR | 12 months Right RAR | 12 months Left RAR | |
| Renal Denervation Group | 1.38 | 1.52 | 1.41 | 1.52 |
Dimensions of renal artery, right and left (NCT01628198)
Timeframe: baseline and 12 months
| Intervention | mm (Mean) | |||
|---|---|---|---|---|
| Baseline R Kidney | Baseline L Kidney | 12 months R Kidney | 12 months L Kidney | |
| Renal Denervation Group | 11.43 | 11.68 | 11.26 | 11.39 |
Renal artery blood flow as measured by Resistive Index. RI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the normal value is ~ 0.60, with 0.70 being around the upper limits of normal (NCT01628198)
Timeframe: Baseline and 12 months
| Intervention | index (Mean) | |||
|---|---|---|---|---|
| Baseline Right RI | Baseline Left RI | 12 months Right RI | 12 months Left RI | |
| Renal Denervation Group | 0.67 | 0.72 | 0.72 | 0.72 |
Plasma levels of dihydroxyphenylglycol are obtained from blood samples via IV catheter. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | nmol/L (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 3.42 | 3.44 | 3.82 | 4.39 |
| Norepinephrine | 4.07 | 4.05 | 4.12 | 4.47 |
| Saline | 4.01 | 3.97 | 4.18 | 5.00 |
Plasma levels of norepinephrine are obtained from blood samples via IV catheter. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | nmol/L (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 0.78 | 0.89 | 1.04 | 1.3 |
| Norepinephrine | 0.73 | 1.99 | 3.73 | 7.83 |
| Saline | 0.82 | 0.65 | 0.97 | 2.32 |
The extent to which norepinephrine infusion maintains blood pressure, by comparison with the changes in diastolic pressure at varying tilt angles during baseline and saline infusion. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 83 | 85 | 79 | 73 |
| Norepinephrine | 95 | 95 | 92 | 98 |
| Saline | 83 | 84 | 81 | 80 |
The extent to which norepinephrine infusion maintains average blood pressure, by comparison with the fractional changes in blood pressure at varying tilt angles during baseline and saline infusion. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 107 | 106 | 96 | 86 |
| Norepinephrine | 123 | 121 | 116 | 124 |
| Saline | 108 | 106 | 97 | 93 |
The extent to which norepinephrine infusion maintains blood pressure, by comparison with the changes in systolic pressure at varying tilt angles during baseline and saline infusion. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 156 | 148 | 131 | 112 |
| Norepinephrine | 179 | 173 | 167 | 175 |
| Saline | 158 | 149 | 128 | 120 |
The extent to which norepinephrine infusion affects cardiac output, by comparison of cardiac output at varying tilt angles during baseline and saline infusion. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | L/min (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 4.6 | 3.9 | 3.4 | 3.4 |
| Norepinephrine | 4.9 | 5.1 | 4.6 | 4.2 |
| Saline | 3.8 | 3.5 | 3.3 | 3.2 |
The extent to which norepinephrine infusion affects cardiac stroke volume, by comparison of cardiac stroke volume at varying tilt angles during baseline and saline infusion. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | mL (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 76 | 70 | 62 | 52 |
| Norepinephrine | 83 | 82 | 76 | 67 |
| Saline | 66 | 62 | 56 | 50 |
The extent to which norepinephrine infusion affects heart rate, by comparison of beat-to-beat heart rate at varying tilt angles during baseline and saline infusion. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | bpm (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 62 | 57 | 55 | 65 |
| Norepinephrine | 58 | 60 | 59 | 63 |
| Saline | 55 | 56 | 58 | 63 |
The extent to which norepinephrine infusion affected total peripheral resistance, by comparison of total peripheral resistance at varying tilt angles during baseline and saline infusion. (NCT01285908)
Timeframe: 2 experimental days
| Intervention | mmHg/(min/L) (Mean) | |||
|---|---|---|---|---|
| Tilt Angle 0 | Tilt Angle 20 | Tilt Angle 40 | Tilt Angle 60 | |
| Baseline | 22.4 | 26.9 | 27.7 | 24.5 |
| Norepinephrine | 27 | 26 | 28 | 31 |
| Saline | 34 | 33 | 32 | 30 |
5 trials available for desipramine and Hypertension
| Article | Year |
|---|---|
Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Blood Pre | 2005 |
Cardiovascular responses to mianserin hydrochloride: a comparison with tricyclic antidepressant drugs.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Bethanidine; Blood Pressure; Cardiovascular | 1978 |
Increased pulse and blood pressure associated with desipramine treatment of bulimia nervosa.
Topics: Adolescent; Adult; Aging; Bulimia; Desipramine; Dose-Response Relationship, Drug; Double-Blind Metho | 1992 |
Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness.
Topics: Adult; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Blood Pressure; Depression; Desipr | 1974 |
Interaction between clonidine and desipramine in man.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Clonidine; Desipramine; Drug Interactions; Female; | 1973 |
28 other studies available for desipramine and Hypertension
| Article | Year |
|---|---|
Ganglion-specific impairment of the norepinephrine transporter in the hypertensive rat.
Topics: Adrenergic Uptake Inhibitors; Animals; Cells, Cultured; Desipramine; Ganglia, Sympathetic; Hypertens | 2013 |
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Adult; Angiotensin II; Biological Transport; Desipr | 2004 |
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Adult; Angiotensin II; Biological Transport; Desipr | 2004 |
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Adult; Angiotensin II; Biological Transport; Desipr | 2004 |
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Adult; Angiotensin II; Biological Transport; Desipr | 2004 |
[Restraining action of antidepressive agents of the imipramine group on the cardiovascular centers].
Topics: Action Potentials; Amitriptyline; Amygdala; Animals; Antidepressive Agents; Blood Pressure; Carotid | 1967 |
Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension.
Topics: Adult; Carbon Radioisotopes; Desipramine; Humans; Hypertension; Isoproterenol; Metabolic Clearance R | 1983 |
Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension.
Topics: Adult; Carbon Radioisotopes; Desipramine; Humans; Hypertension; Isoproterenol; Metabolic Clearance R | 1983 |
Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension.
Topics: Adult; Carbon Radioisotopes; Desipramine; Humans; Hypertension; Isoproterenol; Metabolic Clearance R | 1983 |
Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension.
Topics: Adult; Carbon Radioisotopes; Desipramine; Humans; Hypertension; Isoproterenol; Metabolic Clearance R | 1983 |
Determination of noradrenaline uptake, spillover to plasma and plasma concentration in patients with essential hypertension.
Topics: Adult; Desipramine; Female; Half-Life; Humans; Hydrocortisone; Hypertension; Male; Neurons; Norepine | 1980 |
Norepinephrine reuptake is impaired in skeletal muscle of hypertensive rats in vivo.
Topics: Adipose Tissue; Adrenergic Uptake Inhibitors; Age Factors; Animals; Baroreflex; Blood Pressure; Body | 2001 |
A possible indirect sympathomimetic action of metformin in the arterial vessel wall of spontanously hypertensive rats.
Topics: Animals; Antidepressive Agents; Arteries; Autonomic Fibers, Postganglionic; Desipramine; Drug Intera | 2001 |
Central noradrenergic control of blood pressure.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Cats; Clonidine; Desipramine; Dogs; Drug Interac | 1976 |
Some cardiovascular effects of ST-91 and clonidine.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Animals; Blood Pressure; Clonidine; Desipramine; Do | 1977 |
The interaction of desipramine and the 5-HT uptake inhibitors femoxetine and paroxetine with the acute hypotensive effect of guanethidine in conscious spontaneously hypertensive rats.
Topics: Animals; Anisoles; Blood Pressure; Desipramine; Dioxolanes; Guanethidine; Heart Rate; Hypertension; | 1979 |
Interaction between noradrenergic and serotonergic mechanisms on the central regulation of blood pressure in the rat: a study using experimental central hypertension produced by chemical lesions of the locus coeruleus.
Topics: 5,6-Dihydroxytryptamine; Animals; Blood Pressure; Brain Chemistry; Desipramine; Fenclonine; Heart Ra | 1978 |
Changes in the contractile response of arteires and veins from hypertensive rabbits to sympathetic nerve activity: assessment of some postsynaptic influences.
Topics: Animals; Aorta, Abdominal; Blood Pressure; Blood Vessels; Carotid Arteries; Catechol O-Methyltransfe | 1976 |
Studies on the hypotensive action of alpha-methyldopamine.
Topics: Animals; Blood Pressure; Cats; Deoxyepinephrine; Depression, Chemical; Desipramine; Dopamine; Drug I | 1975 |
Clinical aspects on presynaptic noradrenaline metabolism.
Topics: Chromatography, High Pressure Liquid; Desipramine; Humans; Hypertension; Isoproterenol; Methoxyhydro | 1991 |
The importance of plasma 3,4-dihydroxyphenylglycol (DOPEG) in analyses of the sympathetic nervous system in vivo.
Topics: Adolescent; Adult; Aged; Animals; Clonidine; Desipramine; Female; Humans; Hypertension; Male; Methox | 1990 |
Increased sensitivity to noradrenaline in glucocorticoid-treated rats: the effects of indomethacin and desipramine.
Topics: Animals; Blood Pressure; Desipramine; Dexamethasone; Dose-Response Relationship, Drug; Hypertension; | 1990 |
Differential effects of dopaminergic drugs on open-field behavior of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Clonidine; Desipramine; Dopamine; Dopamine Agents; | 1989 |
Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat. I. The peripheral nervous system.
Topics: Adrenal Glands; Animals; Catecholamines; Desipramine; Heart Rate; Hypertension; Kidney; Male; Periph | 1987 |
Estimation of intrasynaptic norepinephrine concentrations in humans.
Topics: Adult; Blood Pressure; Desipramine; Dose-Response Relationship, Drug; Humans; Hypertension; Male; Mi | 1986 |
Measurement of regional neuronal removal of norepinephrine in man.
Topics: Arm; Biological Transport; Desipramine; Humans; Hypertension; Isoproterenol; Kinetics; Metabolic Cle | 1985 |
[Changes in the hypertensive effects of angiotensin by adrenergic and anti-adrenergic agents].
Topics: Amphetamine; Angiotensin II; Animals; Blood Pressure; Bretylium Compounds; Cocaine; Desipramine; Dib | 1968 |
On the treatment of rapid eye movement narcolepsy.
Topics: Adult; Amphetamine; Antidepressive Agents; Cataplexy; Depression; Desipramine; Electroencephalograph | 1974 |
Distribution of guanidinium antihypertensives--mechanism of their selective action.
Topics: Animals; Antihypertensive Agents; Benzyl Compounds; Biological Transport; Blood Pressure; Desipramin | 1971 |
Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man.
Topics: Antidepressive Agents; Antihypertensive Agents; Blood Pressure; Desipramine; Drug Antagonism; Guanet | 1970 |
[Effect of stimulation of the sympathetic trunk on liberation of noradrenaline 3H into the rat blood stream: influence of guanethidine, phenoxybenzamine, cocaine and desipramine in vivo].
Topics: Adrenalectomy; Animals; Cocaine; Desipramine; Electric Stimulation; Guanethidine; Hexamethonium Comp | 1970 |
Tricyclic antidepressants and monoamine oxidase inhibitors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amitriptyline; Animals; Depression; Desipramine; Drug | 1971 |
Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride.
Topics: Antidepressive Agents; Antihypertensive Agents; Blood Pressure; Desipramine; Drug Antagonism; Guanet | 1967 |
Studies on the hypertensive response elicited by reserpine or tetrabenazine in rats treated with amphetamine-like drugs.
Topics: Amphetamine; Animals; Desipramine; Female; Hypertension; Injections, Intravenous; Male; Monoamine Ox | 1968 |